comprimé orodispersible

DRUG4 trials

Sponsors

Centre Hospitalier Universitaire De Nantes, Karyopharm Therapeutics Inc., Centre Hospitalier Universitaire Amiens Picardie, Centre Hospitalier Universitaire De Lille

Conditions

Alcoholic hepatitisTreatment naïve patients with MFkidney transplantationsuperficial arteriovenous malformations

Phase 2

MAV-RAPA: Prospective evaluation of the efficacy of sirolimus (Rapamune) in the treatment of superficial arteriovenous malformations.

Not yet recruitingCTIS2024-516001-23-00

Centre Hospitalier Universitaire Amiens Picardiesuperficial arteriovenous malformations

Target: 50Updated: 2025-01-17

Phase 3

A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS

Active, not recruitingCTIS2023-506139-13-00

Karyopharm Therapeutics Inc.Treatment naïve patients with MF

Start: 2024-01-04Target: 195Updated: 2025-10-09

Prospective, multicenter, randomized, open-label, parallel-group controlled phase 3 study of tacrolimus minimization in kidney transplant recipients selected according to the AGORA algorithm for their low immunological risk and medium-term graft failure

RecruitingCTIS2022-502624-44-00

Centre Hospitalier Universitaire De Nanteskidney transplantation

Start: 2024-12-10Target: 343Updated: 2024-10-21

PROlonged Corticosteroid treatment or N-ACetylcysteine for severe alcoholic hepatitis (PROCORNAC)

Not yet recruitingCTIS2025-522109-39-00

Centre Hospitalier Universitaire De LilleAlcoholic hepatitis

Target: 477Updated: 2025-10-17